It's never been clearer: our future depends on companies that not only innovate boldly, but ones that act with integrity.
Article
Over the past months, we’ve seen ties between health, progress, and prosperity strain in real time due to the hardships brought on by the pandemic. Life as we know it changed dramatically, as did the role of the private sector in many ways.
MIDLAND, Mich., October 13, 2020 /3BL Media/ – Dow (NYSE: DOW) announced recently that it has been awarded the 2020 National Safety Council (NSC) Green Cross for Safety® Innovation Award.
Dow received the NSC Green Cross for Safety® Innovation Award during the 2020 Green Cross for Safety Awards virtual celebration on October 1 for its Aerial Lift Safety Project, for approaching a lasting challenge and developing a transformative response to the problem.
CRB, a leader in the design and construction of biotech manufacturing facilities, creates SlateXpace – a multimodal facility solution that delivers unmatched industry speed, flexibility and adaptability for the advanced therapy market
Press Release
SAN DIEGO, Calif., Sept. 30, 2020 /3BL Media/ – Emerging health threats, uncured diseases and the need to deliver critical therapies to patients are driving biotech companies to search for ways to build flexibility into their complex product pipelines and deliver projects in record time. Today, a pioneering multi-modality manufacturing solution addresses that challenge: SlateXpace™.
First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S
Press Release
NEW BRUNSWICK, N.J., September 28, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) recently announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development.
by Alex Gorsky Chairman of the Board and Chief Executive Officer, Johnson & Johnson
Blog
It’s hard to believe that just six months have passed since our scientists identified Janssen’s lead COVID-19 vaccine candidate. We couldn’t have predicted all the changes that have happened since. Two things, however, have been constant: COVID-19 continues to be a devastating pandemic, and Johnson & Johnson has been working around the clock on a potential solution.
In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.
As schools reopen—and sometimes close again—what have we learned about the risks of in-person learning? Lisa Ling speaks to school nurse Robin Cogan and pediatrician Dr. Sam Maldonado to find answers and debunk myths around kids and COVID-19.
As part of its new Healthy Lives Mission, the company's iconic consumer brands will aim to use 100% recyclable, reusable or compostable plastic packaging and certified/post-consumer recycled paper- and pulp-based packaging. Learn more about the unique ways the investment will improve the health of people and the earth.
Article
As part of its new Healthy Lives Mission, the company's iconic consumer brands will aim to use 100% recyclable, reusable or compostable plastic packaging and certified/post-consumer recycled paper- and pulp-based packaging. Learn more about the unique ways the investment will improve the health of people and the earth.
